The INTERCEPT Blood System for platelets has demonstrated clinical efficacy for treating and preventing bleeding in clinical trials and in routine use.1
While many studies were performed in haematology/oncology patients, this study focused on the clinical efficacy during massive transfusion.
The retrospective cohort analysis concluded that the introduction of INTERCEPT-treated platelet concentrates did not adversely affect clinical outcomes in massively transfused patients in terms of blood product usage, in-hospital mortality and length of stay for a range of clinical indications for platelet transfusion support.
Results of the study were recently published in Vox Sanguinis - The Internal Journal of Transfusion Medicine.
Nussbaumer, W., Amato, M., Schennach, H., Astl, M., Chen, C. Y., Lin, J.-S., Corash, L. and Benjamin, R. J. (2017), Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang, 112: 249–256. doi:10.1111/vox.12489
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.